VolitionRx Limited announced the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. ("IDEXX") reference laboratory network in the U.S.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
498.5 USD | +3.28% |
|
+3.70% | -10.72% |
03:20pm | Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $589 From $596, Maintains Overweight Rating | MT |
06-24 | Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $520 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
- Stock Market
- Equities
- IDXX Stock
- News IDEXX Laboratories, Inc.
- Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network